Nothing Special   »   [go: up one dir, main page]

Matulic-Adamic et al., 2002 - Google Patents

Synthesis of N-acetyl-D-galactosamine and folic acid conjugated ribozymes

Matulic-Adamic et al., 2002

Document ID
12054635089677606916
Author
Matulic-Adamic J
Serebryany V
Haeberli P
Mokler V
Beigelman L
Publication year
Publication venue
Bioconjugate chemistry

External Links

Snippet

To evaluate potential improvement in tissue specific targeting and cellular uptake of therapeutic ribozymes, we have developed three new phosphoramidite reagents. These reagents can be used in automated solid-phase synthesis to produce oligonucleotide …
Continue reading at pubs.acs.org (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48007—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the pharmacologically- or therapeutically-active agent being covalently bound or complexed to a modifying agent
    • A61K47/48023—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the pharmacologically- or therapeutically-active agent being covalently bound or complexed to a modifying agent the modifying agent being an organic compound
    • A61K47/48092—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the pharmacologically- or therapeutically-active agent being covalently bound or complexed to a modifying agent the modifying agent being an organic compound the modifying agent linked to the pharmacologically or therapeutically active agent being a sugar, nucleoside, nucleotide, nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48238—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid
    • A61K47/48246—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48369—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Similar Documents

Publication Publication Date Title
Maier et al. Synthesis of antisense oligonucleotides conjugated to a multivalent carbohydrate cluster for cellular targeting
Singh et al. Preparation of a multitopic glycopeptide− oligonucleotide conjugate
Rajur et al. Covalent Protein− Oligonucleotide Conjugates for Efficient Delivery of Antisense Molecules
US6300319B1 (en) Targeted oligonucleotide conjugates
Bouillon et al. Microwave assisted “click” chemistry for the synthesis of multiple labeled-carbohydrate oligonucleotides on solid support
Sharma et al. Novel cluster and monomer-based GalNAc structures induce effective uptake of siRNAs in vitro and in vivo
US5574142A (en) Peptide linkers for improved oligonucleotide delivery
Zatsepin et al. Synthesis of peptide− oligonucleotide conjugates with single and multiple peptides attached to 2 ‘-aldehydes through thiazolidine, oxime, and hydrazine linkages
Rashidian et al. Simultaneous dual protein labeling using a triorthogonal reagent
Hamzavi et al. Modulation of the pharmacokinetic properties of PNA: preparation of galactosyl, mannosyl, fucosyl, N-acetylgalactosaminyl, and N-acetylglucosaminyl derivatives of aminoethylglycine peptide nucleic acid monomers and their incorporation into PNA oligomers
Katajisto et al. Solid-phase synthesis of multiantennary oligonucleotide glycoconjugates utilizing on-support oximation
Dey et al. Ketone-DNA: a versatile postsynthetic DNA decoration platform
Petrov et al. New small-molecule glycoconjugates of docetaxel and GalNAc for targeted delivery to hepatocellular carcinoma
Aaronson et al. Rapid HATU-mediated solution phase siRNA conjugation
Wittmann et al. Ligand recognition by E-and P-selectin: chemoenzymatic synthesis and inhibitory activity of bivalent sialyl Lewis x derivatives and sialyl Lewis x carboxylic acids
Lv et al. Synthesis and evaluation of O 2-derived diazeniumdiolates activatable via bioorthogonal chemistry reactions in living cells
Rait et al. 3 ‘-End conjugates of minimally phosphorothioate-protected oligonucleotides with 1-O-hexadecylglycerol: synthesis and anti-ras activity in radiation-resistant cells
Kalovidouris et al. Chemically defined sialoside scaffolds for investigation of multivalent interactions with sialic acid binding proteins
Jezowska et al. Enabling multiple conjugation to oligonucleotides using “click cycles”
Honcharenko et al. New alkyne and amine linkers for versatile multiple conjugation of oligonucleotides
Dai et al. DNA cleavage potency, cytotoxicity, and mechanism of action of a novel class of enediyne prodrugs
Matulic-Adamic et al. Synthesis of N-acetyl-D-galactosamine and folic acid conjugated ribozymes
Ries et al. Synthesis and biophysical investigations of oligonucleotides containing galactose-modified DNA, LNA, and 2′-amino-LNA monomers
Aho et al. Conjugation of oligonucleotides to peptide aldehydes via a Ph-responsive N-methoxyoxazolidine linker
Reshitko et al. Synthesis and evaluation of new trivalent ligands for hepatocyte targeting via the asialoglycoprotein receptor